Who We Are: PMK Group and Our Mission in Biotech | Clinical Capital Conversations
Biotech often fails for the wrong reasons. Nearly 60% of clinical trial failures are due to technical execution, not the science itself.
In this episode, Dr. Peter M. Kovacs explains why he founded PMK Group, a firm that combines capital with clinical and regulatory expertise to reduce technical failures and accelerate drug development.
Why it matters:
– Billions are lost to preventable execution failures
– Patients wait years for therapies that could be delivered faster
– Investors face unnecessary downside risk
PMK Group’s model is different: we do not just invest money. We invest experience, systems, and execution.
Subscribe to Clinical Capital Conversations for more insights at the crossroads of science and capital.
Timecode:
00:00 Introduction to Success in Biotech
00:16 Understanding the Main Risks in Biotech
00:44 Meet the Leader: Peter M. Kovacs
01:06 The PMK Group Difference
01:42 Minimizing Technical Failures
02:09 Supporting Biotech and MedTech Companies
02:32 Vision for the Future
02:58 Call to Collaborate
Links:
Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/
Peter M. Kovacs Personal Website:https://www.petermkovacs.com/
PMK Group Website: https://www.pmk-group.com/
